Sanofi announced today that it will spend €600 million ($685 million) on a new plant in Toronto to produce its differentiated influenza vaccines. The Paris-based pharma giant’s Fluzone high-dose quadrivalent influenza vaccine has four times more antigen than a standard-dose vaccine. The vaccine’s creators specifically designed it to provide superior protection against influenza for older…